Table 3. A, univariate and B, multivariate Cox proportional hazards analyses of clinicopathological variables and gene expression with recurrence-free survival and overall survival in patients that exhibited a complete initial response to adjuvant chemotherapy.

	Recurrence-free survival		Overall survival
Variable	HR (95% CI)	P-valuea	HR (95% CI)	P-value
(A)
Age (years)
⩽60 vs >60	0.95 (0.63–1.42)	0.80	0.79 (0.51–1.21)	0.28
FIGO stage
III/IV vs I/II	3.50 (1.61–7.61)	0.002	4.48 (1.80–11.15)	0.001
Tumour grade
2, 3 vs 1	2.54 (0.80–8.05)	0.11	2.55 (0.79–8.22)	0.12
Surgical debulking
>1 cm vs ⩽1 cm	2.59 (1.69–3.97)	<0.0001	2.27 (1.46–3.52)	0.0001
Menopausal status
Post vs pre/peri	1.14 (0.72–1.80)	0.59	1.61 (0.94–2.74)	0.08
CA125
>500 vs ⩽500	1.42 (0.90–2.22)	0.13	1.08 (0.68–1.71)	0.76
Adjuvant chemotherapy
P only N vs Y	1.38 (0.75–2.54)	0.29	1.14 (0.59–2.21)	0.70
P+C N vs Y	0.86 (0.57–1.29)	0.47	0.98 (0.64–1.51)	0.93
P+T N vs Y	0.90 (0.59–1.38)	0.63	0.93 (0.51–1.48)	0.76
M only N vs Y	1.95 (0.48–7.93)	0.35	1.25 (0.31–5.12)	0.76
EDD expression
High vs low/absent	1.75 (1.14–2.69)	0.011	1.77 (1.11–2.80)	0.016
VEGF expression
>2 vs ⩽2	1.39 (0.92–2.11)	0.12	1.22 (0.78–1.91)	0.38
p53 expression
>10% vs ⩽10%	1.31 (0.84–2.05)	0.24	1.09 (0.68–1.73)	0.73
p21 Wap/Cif1
<10% vs ⩾10%	1.96 (1.03–3.74)	0.04	2.30 (1.14–4.63)	0.02
(B)
FIGO Stage
III/IV vs I/II	3.84 (1.74–8.48)	0.0009	4.61 (1.82–11.66)	0.001
Surgical debulking
>1 cm vs ⩽1 cm	2.60 (1.68–4.02)	<0.0001	1.92 (1.23–3.00)	0.004
EDD expression
High vs low/absent	2.25 (1.44–3.52)	0.0004	1.96 (1.22–3.17)	0.006

C=cyclophosphamide; CI=confidence interval; HR=hazards ratio; M=melphalan; P=platinum; T, paclitaxel.

^aBold type indicates significant P-values.